Us Bancorp \De\ Sage Therapeutics, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 10,162 shares of SAGE stock, worth $58,228. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,162

Previous 9,479 7.21%

Holding current value

$58,228

Previous $102,000 28.43%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$7.02 - $13.08 $4,794 - $8,933	683 Added 7.21%	10,162 $73,000
Q2 2024 Aug 06, 2024	BUY	$10.58 - $17.9 $96,711 - $163,623	9,141 Added 2704.44%	9,479 $102,000
Q1 2024 May 07, 2024	SELL	$18.62 - $26.95 $297 - $431	-16 Reduced 4.52%	338 $6,000
Q4 2023 Feb 09, 2024	SELL	$17.1 - $22.26 $36,354 - $47,324	-2,126 Reduced 85.73%	354 $7,000
Q3 2023 Nov 03, 2023	BUY	$16.75 - $48.98 $20,803 - $60,833	1,242 Added 100.32%	2,480 $51,000
Q2 2023 Aug 09, 2023	SELL	$40.65 - $59.54 $1,626 - $2,381	-40 Reduced 3.13%	1,238 $58,000
Q1 2023 May 09, 2023	BUY	$37.27 - $46.57 $4,658 - $5,821	125 Added 10.84%	1,278 $53,000
Q4 2022 Feb 13, 2023	SELL	$32.2 - $43.61 $9,048 - $12,254	-281 Reduced 19.6%	1,153 $43,000
Q3 2022 Oct 27, 2022	SELL	$32.28 - $43.27 $13,848 - $18,562	-429 Reduced 23.03%	1,434 $56,000
Q2 2022 Aug 01, 2022	BUY	$27.52 - $37.99 $12,576 - $17,361	457 Added 32.5%	1,863 $60,000
Q1 2022 May 11, 2022	SELL	$30.71 - $45.71 $7,769 - $11,564	-253 Reduced 15.25%	1,406 $47,000
Q4 2021 Feb 11, 2022	SELL	$37.06 - $47.11 $8,375 - $10,646	-226 Reduced 11.99%	1,659 $71,000
Q3 2021 Nov 10, 2021	BUY	$40.26 - $57.37 $12,480 - $17,784	310 Added 19.68%	1,885 $84,000
Q2 2021 Aug 05, 2021	SELL	$54.88 - $79.29 $1,646 - $2,378	-30 Reduced 1.87%	1,575 $89,000
Q1 2021 Apr 28, 2021	SELL	$70.65 - $96.76 $105,268 - $144,172	-1,490 Reduced 48.14%	1,605 $121,000
Q4 2020 Feb 04, 2021	BUY	$58.41 - $89.06 $15,128 - $23,066	259 Added 9.13%	3,095 $267,000
Q3 2020 Nov 10, 2020	BUY	$41.13 - $62.45 $79,380 - $120,528	1,930 Added 213.02%	2,836 $173,000
Q2 2020 Aug 07, 2020	BUY	$25.95 - $43.15 $9,056 - $15,059	349 Added 62.66%	906 $38,000
Q1 2020 May 13, 2020	BUY	$26.15 - $77.24 $7,766 - $22,940	297 Added 114.23%	557 $16,000
Q4 2019 Feb 04, 2020	SELL	$60.18 - $154.77 $57,171 - $147,031	-950 Reduced 78.51%	260 $19,000
Q3 2019 Nov 08, 2019	BUY	$140.29 - $189.96 $12,345 - $16,716	88 Added 7.84%	1,210 $170,000
Q2 2019 Aug 13, 2019	BUY	$157.85 - $183.09 $10,418 - $12,083	66 Added 6.25%	1,122 $205,000
Q1 2019 May 08, 2019	BUY	$89.33 - $163.65 $90,669 - $166,104	1,015 Added 2475.61%	1,056 $168,000
Q4 2018 Feb 13, 2019	SELL	$81.94 - $139.71 $65,961 - $112,466	-805 Reduced 95.15%	41 $3,000
Q3 2018 Nov 01, 2018	SELL	$138.11 - $169.04 $1,104 - $1,352	-8 Reduced 0.94%	846 $119,000
Q2 2018 Aug 08, 2018	BUY	$140.36 - $175.76 $117,762 - $147,462	839 Added 5593.33%	854 $133,000
Q4 2017 Feb 02, 2018	SELL	$60.72 - $167.34 $3,218 - $8,869	-53 Reduced 77.94%	15 $2,000
Q3 2017 Nov 13, 2017	BUY	$61.4 - $88.52 $4,175 - $6,019	68	68 $4,000

Others Institutions Holding SAGE

# of Institutions

218

Shares Held

46.4M

Call Options Held

847K

Put Options Held

188K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account